Andrew M. Skinner
No Rating Available
(Learn About Our Rating System)

Andrew M. Skinner, MD

Languages spoken: English

Clinical Locations

University of Utah Hospital

Salt Lake City
801-581-8812

Veterans Administration Medical Center

Salt Lake City

  • Specialties

    Board Certification

    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Infectious Disease)

  • Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Infectious Diseases
    Board Certification
    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Infectious Disease)

    Education history

    Fellowship Infectious Disease Research - Loyola University Medical Center Fellow
    Fellowship Infectious Disease - Loyola University Medical Center Fellow
    Residency Internal Medicine - University of Chicago Medicine at NorthShore Chief Resident
    Residency Internal Medicine - University of Chicago Medicine at NorthShore Resident
    Professional Medical Medicine - University of South Alabama College of Medicine M.D.
    Undergraduate Biomedical Sciences - Auburn University B.S.

    Selected Publications

    Journal Article

    1. Drwiega EN, Johnson S, Danziger LH, Skinner AM (2024). Risk of rehospitalization due to Clostridioides difficile infection among hospitalized patients with Clostridioides difficile: a cohort study. Infect Control Hosp Epidemiol, 1-7. (Read full article)
    2. Hunt A, Danziger LH, Johnson S, Skinner AM (2024). Management and Outcomes of Patients at a Specialty Clinic for C. difficile Infection. Open Forum Infectious Diseases, ofae153.
    3. Feuerstadt P, Crawford CV, Tan X, Pokhilko V, Bancke L, Ng S, Guthmueller B, Bidell MR, Tillotson G, Johnson S, Skinner AM (2023). Fecal Microbiota, Live-jslm for the Prevention of Recurrent Clostridioides difficile Infection: Subgroup Analysis of PUNCH CD2 and PUNCH CD3. J Clin Gastroenterol. (Read full article)
    4. Skinner AM, Tan X, Westman C, Birris T, Drwiega E, Wang MS, Johnson S (2023). Efficacy of bezlotoxumab to prevent recurrent Clostridioides difficile infection (CDI) in patients with multiple prior recurrent CDI. Anaerobe, 102788. (Read full article)
    5. van Prehn J, van Werkhoven CH, Skinner AM, Guery B, Dubberke ER, Kuijper EJ (2023). Which trial do we need? A sequential multiple assignment randomized trial to determine the optimal Clostridioides difficile treatment sequence. Clin Microbiol Infect. (Read full article)
    6. Crone AS, Wright LM, Cheknis A, Johnson S, Pacheco SM, Skinner AM (2023). Characteristics and outcomes of Clostridioides difficile infection after a change in the diagnostic testing algorithm. Infect Control Hosp Epidemiol, 1-6. (Read full article)
    7. Wright LM, Skinner AM, Cheknis A, McBurney C, Ge L, Pacheco SM, Leehey D, Gerding DN, Johnson S (2023). Effect of the COVID-19 Pandemic on Rates and Epidemiology of Clostridioides difficile Infection in One VA Hospital. Antibiotics (Basel), 12(7). (Read full article)
    8. Skinner AM, Petrella LA, Cheknis A, Johnson S (2023). Antimicrobial susceptibility of Clostridioides difficile to omadacycline and comparator antimicrobials. J Antimicrob Chemother. (Read full article)
    9. Sambol SP, Skinner AM, Serna-Perez F, Owen B, Gerding DN, Johnson S (2023). Effective Colonization by Nontoxigenic Clostridioides difficile REA Strain M3 (NTCD-M3) Spores following Treatment with Either Fidaxomicin or Vancomycin. Microbiol Spectr, 11(2), e0051723. (Read full article)
    10. Chang LL, Allegretti J, Skinner AM, Dubberke ER (2023). Oral Vancomycin as Secondary Prophylaxis for Prevention of Recurrent Clostridioides difficile Infection. N Engl J Med, 388(7), 654-656. (Read full article)
    11. Skinner AM, Petrella L, Spandoni S, Serna-Perez F, Johnson S (2022). Can Clostridium innocuum Masquerade as Clostridioides difficile? Clin Infect Dis, 75(7), 1268-1269. (Read full article)
    12. Skinner AM, Tan X, Sirbu BD, Danziger LH, Gerding DN, Johnson S (2021). A Tapered-pulsed Fidaxomicin Regimen Following Treatment in Patients With Multiple Clostridioides difficile Infection Recurrences. Clin Infect Dis, 73(6), 1107-1109. (Read full article)
    13. Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, Wilcox MH (2021). Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis, 73(5), e1029-e1044. (Read full article)
    14. Skinner AM, Phillips ST, Merrigan MM, OLeary KJ, Sambol SP, Siddiqui F, Peterson LR, Gerding DN, Johnson S (2020). The Relative Role of Toxins A and B in the Virulence of Clotridioides difficile. J Clin Med, 10(1). (Read full article)
    15. Skinner AM, Yu B, Cheknis A, Pacheco SM, Gerding DN, Johnson S (2020). Sequential introduction of a multistep testing algorithm and nucleic acid amplification testing leading to an increase in Clostridioides difficile detection and a trend toward increased strain diversity. Infect Control Hosp Epidemiol, 41(10), 1148-1153. (Read full article)
    16. Skinner AM, Scardina T, Kociolek LK (2020). Fidaxomicin for the treatment of Clostridioides difficile in children. Future Microbiol, 15(11), 967-979. (Read full article)
    17. Skinner AM, Petrella L, Siddiqui F, Sambol SP, Gulvik CA, Gerding DN, Donskey CJ, Johnson S (2020). Unique Clindamycin-Resistant Clostridioides difficile Strain Related to Fluoroquinolone-Resistant Epidemic BI/RT027 Strain. Emerg Infect Dis, 26(2), 247-254. (Read full article)
    18. Peterson LR, Samia NI, Skinner AM, Chopra A, Smith B (2017). Antimicrobial Stewardship Lessons From Mupirocin Use and Resistance in Methicillin-Resitant Staphylococcus Aureus. Open Forum Infect Dis, 4(2), ofx093. (Read full article)

    Review

    1. Gonzales-Luna AJ, Skinner AM, Alonso CD, Bouza E, Cornely OA, de Meij TGJ, Drew RJ, Garey KW, Gerding DN, Johnson S, Kahn SA, Kato H, Kelly CP, Kelly CR, Kociolek LK, Kuijper EJ, Louie T, Riley TV, Sandora TJ, Vehreschild MJGT, Wilcox MH, Dubberke ER, EXPAND Cdiff group (2023). Redefining Clostridioides difficile infection antibiotic response and clinical outcomes. [Review]. Lancet Infect Dis. (Read full article)

    Book Chapter

    1. Suk M, Skinner AM, Mahajan S, Franklin C (2018). Judicial Involvement in End-of-LifeDecisions and Informed Consent. In Yu M, Gabrielli A, Wood KE, Layon AJ (Eds.), Civetta, Taylor, & Kirby's Critical Care Medicine (5th Edition, pp. 21-32). Philadelphia, PA: Lippincott Williams & Wilkins.

    Letter

    1. van Prehn J, Skinner AM, Krutova M, Guery B (2023). Re: 'The effect of antibiotic therapy for Clostridioides difficile infection on mortality and other patient-relevant outcomes' by Stabholz et al. [Letter to the editor]. Clin Microbiol Infect, 30(2), 261-262. (Read full article)
    2. van Prehn J, Skinner A, Krutova M, Guery B (2023). Re: 'the effect of antibiotic therapy for Clostridioides difficile infection on mortality and other patient-relevant outcomes' by Stabholz et al. [Letter to the editor]. Clin Microbiol Infect, 30(2), 261-262. (Read full article)